Medical professionals are raising concerns about patients who discontinue popular weight loss medications experiencing significant weight regain.

The National Institute for Health and Care Excellence has highlighted that individuals using injectable treatments such as Wegovy and Mounjaro frequently recover much of their lost weight once they cease taking the drugs.

These medications have seen widespread adoption, with approximately 15.5 million American adults utilising them for managing type 2 diabetes or reducing obesity.

However, healthcare experts now emphasise the critical challenge patients face in maintaining their weight loss achievements after treatment ends, despite initial programmes incorporating dietary modifications and increased physical activity.

GETTY

Clinical evidence demonstrates the extent of weight regain following treatment cessation. Research involving Wegovy participants showed that approximately two-thirds of their initial weight returned after stopping the injections.

Studies examining Mounjaro produced comparable findings, with investigators noting that discontinuation resulted in considerable recovery of previously lost weight.

A comprehensive Chinese analysis tracking 2,466 individuals revealed that notable weight increases emerged merely eight weeks following the conclusion of anti-obesity medication programmes.

These findings underscore the temporary nature of pharmaceutical weight reduction when treatments are withdrawn, highlighting the necessity for ongoing support mechanisms to sustain the health benefits achieved during active medication periods.

The National Institute for Health and Care Excellence has responded by implementing immediate new standards across UK healthcare services.

These guidelines mandate that medical providers deliver comprehensive, personalised support and continued monitoring for individuals completing weight loss medication programmes.

"Weight management is a long-term journey, not a short-term fix," stated Dr Rebecca Payne, who chairs NICE's Quality Standards Advisory Committee.

She emphasised that structured guidance and ongoing assistance following medication cessation or behavioural programme completion help prevent weight regain whilst preserving achieved health improvements.

GETTY |

Discontinuation may result in considerable recovery of previously lost weight

The new framework requires healthcare commissioners and providers to establish continuous care pathways extending beyond active treatment phases.

The recommended support structures encompass professional nutritional guidance, participation in community exercise programmes, and utilisation of digital monitoring resources.

Healthcare providers must assist patients in modifying their domestic and professional environments to accommodate healthier routines whilst encouraging engagement with local and online support networks.

Professor Jonathan Benger, NICE's deputy chief executive and chief medical officer, explained that effective weight management extends beyond medication completion or behavioural programme conclusion.

He noted the transition phase represents a vital period requiring organised assistance to preserve beneficial lifestyle modifications.

"We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made," Professor Benger stated.